Professor Emeritus

Welcome to the latest installment of C9 Conversations. For this episode, we were very fortunate to get a chance to converse openly with one of the world’s preeminent mathematical logicians, the great Yuri Gurevich.

Dr. Gurevich is Professor Emeritus of Electrical Engineering and Computer Science at the University of Michigan. He is currently a principle research scientist in Wolfram Schulte’s RiSE team (Research in Software Engineering group at Microsoft Research).

Originally, Dr. Gurevich started his career as an algebraist. Later he became a logician. Then he moved to computer science, where his main projects have been Abstract State Machines, Average Case Computational Complexity, and Finite Model Theory. Dr. Gurevich has been honored as a Dr. Honoris Causa of the University of Limburg, Belgium (1998), as a Fellow of the Association for Computing Machinery (1996), as well as a Fellow of the John Simon Guggenheim Memorial Foundation (1995).

Dr. Gurevich’s fundamental work on the theory of Abstract State Machines (ASMs) is of paramount importance for theoretical and applied computer science. The significance of the theoretical concepts developed by Gurevich is confirmed by the substantial impact they have on mathematical modeling of discrete dynamic systems.

*This is probably the only interview in C9’s history where a good case is made for imperative programming versus declarative and functional (this starts right off the bat at around 02:31).

Read Yuri’s Annotated Articles

Tune in. Meet Yuri Gurevich.

Practical Life Extension Results

Google Tech Talk October 9, 2009 ABSTRACT Presented by Gregory Benford. Genescient is the world's first computational biology company founded on the use of artificial biological selection to cure the diseases of aging. Our laboratory animals have been selected for longevity through 750 generations for the equivalent of 15000 human years. I will describe Genescient's multiple pathways toward accelerating human longevity, with parallel enhancements of vigor and function. Genescient applies 21st century genomic technology to identify, screen and develop benign therapeutic substances at precise doses, to defeat the diseases of aging. Our singular approach addresses the complex genomic networks that underlie aging and aging-associated diseases such as cardiovascular disease, Type II diabetes and neurodegenerative diseases. I shall display some results and our first product, due in 2009. Gregory Benford is a Professor Emeritus at the University of California, Irvine, where he was a Professor of Physics. He is a Woodrow Wilson Fellow, a Fellow of the American Physical Society and was Visiting Fellow at Cambridge University and the Universities of Turin and Bologna. In 1995 he received the Lord Prize for contributions to science. With more than 200 scientific publications, his research encompasses both theory and experiments in the fields of astrophysics and plasma physics. His research has been supported by NSF, NASA, AFOSR, DOE and other agencies. He is an ongoing advisor to <b>…</b>

52
ratings

Time:
52:55
More in
Science & Technology

C9 Conversations: Yuri Gurevich On Logic, Imperative, Abstraction and Algorithms

Practical Life Extension Results

Tags